
CDAKQ
Healthcare · Biotechnology
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jul 5, 2023 | After the close | -0.30 | 0.00 | +100.0% |
| Jun 29, 2023 | After the close | -0.32 | -0.34 | -5.1% |
| Mar 15, 2023 | Time not confirmed | -0.39 | -0.36 | +6.4% |
| Nov 3, 2022 | After the close | -0.82 | -0.77 | +6.1% |
| Aug 4, 2022 | After the close | -0.84 | -0.30 | +64.3% |
| May 5, 2022 | After the close | -0.89 | -0.36 | +59.6% |
| Mar 10, 2022 | After the close | -0.94 | 0.74 | +178.7% |
| Nov 4, 2021 | After the close | -0.94 | -0.97 | -3.2% |
| Aug 5, 2021 | After the close | -1.05 | -0.99 | +5.7% |
| May 6, 2021 | After the close | -1.09 | -0.51 | +53.2% |
| Mar 17, 2021 | Before the open | -1.54 | -1.14 | +26.0% |
| Oct 14, 2020 | After the close | -5.50 | -12.83 | -133.3% |
| Sep 2, 2020 | Time not confirmed | — | -6.40 |
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an…
| — |
| Apr 29, 2019 | Time not confirmed | — | -0.14 | — |